NCT05625893招募中2 期
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion: PORTAL Study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0)
研究概览
简要总结
This study is investigator initiated, single-institution, prospective, phase 2 open-label study to determine the efficacy and safety of combination therapy of atezolizumab/bevacizumab and proton beam therapy to portal vein tumor thrombosis with or without main primary tumor in patients with stage 3 or higher hepatocellular carcinoma (HCC) with Vp2-4 portal vein invasion who had not undergone systemic therapy for HCC. The primary endpoint of this study is progression-free survival and secondary endpoints are overall survival (OS), time to progression (TTP), objective response rate, disease control rate (DCR), and time to local disease progression (LTP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with HCC meeting all of following criteria;
- •Histologically or radiologically confirmed hepatocellular carcinoma based on the guidelines of the Korean Liver Cancer Association-National Cancer Center 2022
- •Vp2-4 portal vein tumor thrombosis diagnosed by dynamic enhanced computed tomography (CT) or maganetic resonance images (MRI) with below finding 1) an intraluminal filling defect adjacent to the primary tumor in Vp2-4 portal vein 2) an enhancement of the filling defect on arterial phase and a washout on portal/delayed phases.
- •Signed written informed consent
- •at least one or more measurable intrahepatic viable HCC lesions
- •Child-Pugh class A within 2 weeks from screening for study registration
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 within 2 weeks from screening for study registration
- •Life expectancy of at least 16 weeks
- •adequate bone marrow and liver function within 2 weeks from screening for study registration
- •Hemoglobin ≥ 9.0 g/dL
- •Absolute neutrophil count (ANC) ≥ 1,000/mm3
- •Platelet count ≥ 50,000/μL
- •Total bilirubin < 2.5 mg/dL
- •Serum albumin >2.8 g/dL
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × upper limit of normal (ULN)
- •Prothrombin time in INR ≤ 1.8 × ULN
- •Serum creatinine ≤ 1.5 mg/dL
- •Women of childbearing potential and men must agree to use highly efficient contraception since signing of the informed consent form until at least 6 months (women) and 7 months (men) after the last study drug administration
- •If other selection conditions are satisfied and the exclusion criteria are not met, registration is possible even in case of N1 or M
- •Registration is possible even in the case of hepatic vein tumor infiltration if other selection conditions are satisfied and the exclusion criteria are not met
- •no limitation according to the size and number of tumors in the liver.
排除标准
- •Patients with HCC meeting all of following criteria;
- •previous history of systemic treatment for HCC (If systemic treatment for HCC has been performed at least once, it will not be enrolled in this study.) However, registration is permitted if the previous systemic treatment is for adjuvant purposes or treatment for other cancers. Also allowed if previous HCC treatment is local treatment. However, cases with a history of previous upper abdominal radiotherapy (including proton therapy and heavy particle therapy) are excluded.
- •any type of anticancer agent (including investigational) within 2 weeks before enrollment
- •Having active brain metastasis or leptomeningeal metastasis need surgery or steroid therapy
- •Moderate to severe or intractable ascites
- •A history or presence of hepatic encephalopathy
- •Presence of active bacterial infection
- •Untreated active chronic hepatitis B or active hepatitis C
- •History of portal hypertension with bleeding within the past 6 months
- •Prior liver transplant
- •Uncontrolled severe medical comorbidity
- •unhealed wound
- •uncontrolled electrolyte imbalance
- •Non-interruptible therapeutic use of anticoagulants or thrombolytics
- •History of uncontrolled or autoimmune disease, or immunocompromised
- •interstitial lung disease
- •Other malignant disease (a history of treated malignancy -other than HCC- is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years)
- •Mentally retarded/medically incapable of consent
结局指标
主要结局
Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0)
时间窗: From date of atezolizumab and bevacizumab initiatton until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months
Progression-free survival rate
时间窗: At 9 month
次要结局
- Objective response rate(At 3 month)
- Disease Control rate(At 3 month)
- Local tumor progression rate(At 12 month)
- Overall survival rate(At 12 month)
- Time-to-progression(At 9 months)
研究者
Jeong Il Yu
Assistant Professor
Samsung Medical Center
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Proton beam radiotherapy followed by Tecentriq(R) amd Avastin(R) for primary liver cancer with protal vein InvasioNeoplasmsKCT0008001Samsung Medical Center32
终止
1 期
Proton Therapy and Bevacizumab for Primary Liver TumorsHepatocellular CarcinomaLiver CancerCholangiocarcinomaNCT00426829M.D. Anderson Cancer Center3
招募中
2 期
The Clinical Study of Post-operative Proton Radiotherapy for Thymus TumorThymus Epithelial TumorProton RadiotherapyRadiation ToxicityNCT06311968Jian Chen55
已完成
不适用
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate CancerProstate CancerNCT01040624University of Florida77
终止
1 期
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung CancerLocally Advanced Non-Small Cell Lung CancerNCT00614484Loma Linda University28